Analyst Ratings For Evolent Health (NYSE:EVH)
Today, Wells Fargo & Co lowered its price target on Evolent Health (NYSE:EVH) to $20.00 per share.
Some recent analyst ratings include
- 1/4/2018-Citigroup initiated coverage with a Buy rating.
- 12/3/2017-Cantor Fitzgerald Reiterated Rating of Buy.
- 11/7/2017-Goldman Sachs Group was Downgraded by analysts at Goldman Sachs Group from a “Conviction-Buy ” rating to a ” Buy” rating.
- 11/3/2017-SunTrust Banks Reiterated Rating of Buy.
Recent Insider Trading Activity For Evolent Health (NYSE:EVH)
Evolent Health (NYSE:EVH) has insider ownership of 8.79% and institutional ownership of 96.77%.
- On 8/3/2017 Frank J. Williams, CEO, sold 16,300 with an average share price of $23.73 per share and the total transaction amounting to $386,799.00.
- On 8/1/2017 Steve Wigginton, CEO, sold 6,000 with an average share price of $24.64 per share and the total transaction amounting to $147,840.00.
- On 7/24/2017 Thomas Peterson III, COO, sold 40,540 with an average share price of $26.00 per share and the total transaction amounting to $1,054,040.00.
- On 7/10/2017 Nicholas Mcgrane, CFO, sold 1,667 with an average share price of $25.42 per share and the total transaction amounting to $42,375.14.
- On 7/6/2017 Frank J. Williams, CEO, sold 16,300 with an average share price of $24.76 per share and the total transaction amounting to $403,588.00.
- On 7/3/2017 Steve Wigginton, CEO, sold 6,000 with an average share price of $25.07 per share and the total transaction amounting to $150,420.00.
- On 6/28/2017 Tpg Growth Ii Advisors, Inc., Insider, sold 4,279,325 with an average share price of $25.87 per share and the total transaction amounting to $110,706,137.75.
Recent Trading Activity for Evolent Health (NYSE:EVH)
Shares of Evolent Health closed the previous trading session at 14.75 up +0.75 5.36% with 15.050000190734863 shares trading hands.